{
    "clinical_study": {
        "@rank": "75435", 
        "arm_group": [
            {
                "arm_group_label": "Autologous bone grafting", 
                "arm_group_type": "Active Comparator", 
                "description": "autologous bone of the iliac crest"
            }, 
            {
                "arm_group_label": "rhBMP-2", 
                "arm_group_type": "Experimental", 
                "description": "Inductos, recombinant human bone morphogenetic protein"
            }
        ], 
        "brief_summary": {
            "textblock": "When there is a bone defect, bone transport is used to bridge the defect. Frequently, the\n      bone in the docking site (where the transported bone comes together) doesn't heal.\n\n      The objective is to study the effectivity of rhBmp-2 (inductos) to stimulate bone healing,\n      in order to find new techniques to treat non-union of long bones.\n\n      The method of the study is a randomized controlled trial, to compare rhBMP-2 and autologous\n      bone grafting in stimulating bone healing in the docking site."
        }, 
        "brief_title": "rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Bone Healing", 
            "Bone Morphogenetic Proteins", 
            "Bone Transport"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients treated with bone transport (Ilizarov technique) and have non-union of the\n             docking site, which is characterized by absence of bridging callus after two months\n             of compression in the docking site.\n\n        Exclusion Criteria:\n\n          -  Allergy for inductos\n\n          -  active growth,\n\n          -  malignancy\n\n          -  infection\n\n          -  PAD\n\n          -  pathological fracture"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01756144", 
            "org_study_id": "2012-005664-10"
        }, 
        "intervention": {
            "arm_group_label": [
                "Autologous bone grafting", 
                "rhBMP-2"
            ], 
            "intervention_name": "rhBMP-2", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 19, 2012", 
        "number_of_arms": "2", 
        "official_title": "rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Belgium: Federal Agency for Medicinal Products and Health Products", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Bone healing in the docking site", 
            "safety_issue": "No", 
            "time_frame": "up to 4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01756144"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Universitaire Ziekenhuizen Leuven", 
            "investigator_full_name": "Dr Jan Vanderstappen", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Infection", 
                "safety_issue": "Yes", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "Edema", 
                "safety_issue": "Yes", 
                "time_frame": "up to one year"
            }, 
            {
                "measure": "cancer", 
                "safety_issue": "Yes", 
                "time_frame": "up to one year"
            }
        ], 
        "source": "Universitaire Ziekenhuizen Leuven", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Universitaire Ziekenhuizen Leuven", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}